DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Neutral impactResults

Alembic Pharmaceuticals Limited — Outcome of Board Meeting

NSE 3 hrs ago·4 Aug 2026, 8:40 am

Company NSE

Alembic Pharmaceuticals has announced the financial results for the period ending June 30, 2026. The company has submitted these details to the stock exchange, marking the standard disclosure required for listed entities. This update provides investors with the latest performance data for the company.

The release of these results is a routine corporate action that allows the market to assess the company's current financial standing. For investors, this information is essential for tracking the company's progress and making informed decisions based on the latest available data.

Investors should focus on the key financial metrics presented in the results, such as revenue growth and profitability. Monitoring these figures will help gauge the company's operational health and future outlook.